The effect of the combination of prostate-specific antigen derivatives with multiparametric prostate magnetic resonance imaging scores on the negative predictive value of it in grey zone patients
To calculate the negative predictive value (NPV) of negative multiparametric prostate magnetic resonance imaging (mpMRI), accepted as no lesions on images, when combined with prostate-specific antigen density (PSAD) and free/total prostate-specific antigen ratio (f/t PSA) in grey zone patients. 191...
Gespeichert in:
| Veröffentlicht in: | Actas urológicas españolas (English ed.) 2024-04, Vol.48 (3), p.238-245 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 245 |
|---|---|
| container_issue | 3 |
| container_start_page | 238 |
| container_title | Actas urológicas españolas (English ed.) |
| container_volume | 48 |
| creator | Bostancı, C. Demir, D.Ö. |
| description | To calculate the negative predictive value (NPV) of negative multiparametric prostate magnetic resonance imaging (mpMRI), accepted as no lesions on images, when combined with prostate-specific antigen density (PSAD) and free/total prostate-specific antigen ratio (f/t PSA) in grey zone patients.
191 patients with PSA levels between 4−10 mg/mL and negative mpMRI were analyzed. The NPV of negative mpMRI was calculated according to a PSAD level of 0.15, and a combination of both. Patients were divided into three risk groups according to these two parameters, which were PSAD 0.01−0.07 ng/mL/mL and f/t PSA ratio ≥25 in a low-risk group, PSAD 0.08−0.15 ng/mL/mL, and f/t PSA ratio 0.15−0.24 in an intermediate-risk group and high-risk group, in which PSAD > 0.15 ng/mL/mL and f/t PSA ratio 0.15 ng/mL/mL and the f/t PSA ratio is 0,15 ng/mL/mL e índice PSA l/t PSA |
| doi_str_mv | 10.1016/j.acuroe.2023.10.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2877380649</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2173578623001154</els_id><sourcerecordid>2877380649</sourcerecordid><originalsourceid>FETCH-LOGICAL-c241t-3735aaac8df0a22723ea82be05386316c9e59172f9b119a2a4582235cf7b8ba83</originalsourceid><addsrcrecordid>eNp9Uctu1TAQtRCIVqV_gJCXbHIb23k4GyRU8ahUiU1ZWxNnkvoqsS-2c1H5PX6MSW-LWOGNx0dn5njOYeytKHeiFM3Vfgd2jQF3spSKoF1ZVi_YuRStKupWNy__qc_YZUr7kk5TqbpTr9mZarXSSjbn7PfdPXIcR7SZh5Fnetmw9M5DdsFv0CGGlCFjkQ5o3egsB5_dhJ4PGN2ReEdM_KfL93xZ5-wOEGHBHIn43MoXmDxmQiKm4MFb5I4w5yeebCCQk9am7XF6HEitODj7WB5hXnH7icvceT5FfOC_gicOUdHn9Ia9GmFOePl0X7Dvnz_dXX8tbr99ubn-eFtYWYlcqFbVAGD1MJYgZSsVgpY9lrXSjRKN7bDuRCvHrheiAwlVraVUtR3bXveg1QV7f5pLe_1YMWWzuGRxnsFjWJORum2VJpc7olYnqiULUsTRHCJtHB-MKM2WoNmbU4JmS3BDKUFqe_eksPYLDn-bnvMiwocTAWnPo8NokiUPLJkVKUIzBPd_hT8egrO9</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2877380649</pqid></control><display><type>article</type><title>The effect of the combination of prostate-specific antigen derivatives with multiparametric prostate magnetic resonance imaging scores on the negative predictive value of it in grey zone patients</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Bostancı, C. ; Demir, D.Ö.</creator><creatorcontrib>Bostancı, C. ; Demir, D.Ö.</creatorcontrib><description><![CDATA[To calculate the negative predictive value (NPV) of negative multiparametric prostate magnetic resonance imaging (mpMRI), accepted as no lesions on images, when combined with prostate-specific antigen density (PSAD) and free/total prostate-specific antigen ratio (f/t PSA) in grey zone patients.
191 patients with PSA levels between 4−10 mg/mL and negative mpMRI were analyzed. The NPV of negative mpMRI was calculated according to a PSAD level of <0.15 ng/mL/mL, f/t PSA ratio of >0.15, and a combination of both. Patients were divided into three risk groups according to these two parameters, which were PSAD 0.01−0.07 ng/mL/mL and f/t PSA ratio ≥25 in a low-risk group, PSAD 0.08−0.15 ng/mL/mL, and f/t PSA ratio 0.15−0.24 in an intermediate-risk group and high-risk group, in which PSAD > 0.15 ng/mL/mL and f/t PSA ratio <15.
NPV of negative mpMRI was 92.6% for clinically significant prostate carcinoma (CSPCa). It increased to 97.5% in a low-risk group and decreased to 33.3% for CSPCa in a high-risk group. NPV of negative mpMRI results were so close when combined with PSAD < 0.15 ng/mL/mL and f/t PSA > 15.
f/t PSA ratio might also be used to increase the NPV of mpMRI, like PSAD. We advise not to avoid prostate biopsy when PSAD is >0.15 ng/mL/mL and the f/t PSA ratio is <0.15. However, we need randomized controlled studies with more patients to confirm our study.
Calcular el valor predictivo negativo (VPN) de la resonancia magnética multiparamétrica (RMmp) de próstata negativa, definida como la ausencia de lesiones en las imágenes, cuando se combina con la densidad del PSA (DPSA) y el índice PSA libre/total (PSA l/t) en pacientes cuyo PSA se encuentra en la zona gris (4−10 mg/mL).
Se analizaron 191 pacientes con niveles de PSA entre 4 y 10 mg/mL y RMmp negativa. El VPN de la RMmp negativa se calculó de acuerdo con un nivel de DPSA < 0,15 ng/mL/mL, un índice PSA l/t > 0,15 y una combinación de ambos. Los pacientes se dividieron en tres grupos de riesgo según estos dos parámetros, de la siguiente manera: DPSA 0,01−0,07 ng/mL/mL e índice PSA l/t ≥ 25 en el grupo de bajo riesgo; DPSA 0,08−0,15 ng/mL/mL e índice PSA l/t 0,15−0,24 en el grupo de riesgo intermedio; DPSA > 0,15 ng/mL/mL e índice PSA l/t PSA < 15 en el grupo de riesgo alto.
El VPN de la RMmp negativa fue del 92,6% para el carcinoma de próstata clínicamente significativo (CPCS). El VPN aumentó a 97,5% en el grupo de riesgo bajo, y disminuyó a 33,3% en el de riesgo alto. El resultado al combinar la RMmp negativa con la DPSA < 0,15 ng/mL/mL fue muy similar al de su combinación con el PSA l/t > 15.
el índice PSA l/t también podría utilizarse para aumentar el VPN de la RMmp, al igual que la DPSA. No recomendamos evitar la biopsia de próstata con una DPSA > 0,15 ng/mL/mL y un índice PSA l/t < 0,15. Sin embargo, se requieren estudios controlados aleatorizados con más pacientes para confirmar los hallazgos de nuestro estudio.]]></description><identifier>ISSN: 2173-5786</identifier><identifier>EISSN: 2173-5786</identifier><identifier>DOI: 10.1016/j.acuroe.2023.10.004</identifier><identifier>PMID: 37838326</identifier><language>eng</language><publisher>Spain: Elsevier España, S.L.U</publisher><subject>Densidad del antígeno prostático específico ; Free/total prostate-specific antigen ratio ; Humans ; Male ; Multiparametric Magnetic Resonance Imaging ; Multiparametric prostate magnetic resonance imagin ; Predictive Value of Tests ; Prostate - diagnostic imaging ; Prostate - pathology ; Prostate specific antigen density ; Prostate-Specific Antigen ; Prostatic Neoplasms - diagnostic imaging ; Prostatic Neoplasms - pathology ; Resonancia magnética multiparamétrica de próstata ; Índice de antígeno prostático específico libre/total</subject><ispartof>Actas urológicas españolas (English ed.), 2024-04, Vol.48 (3), p.238-245</ispartof><rights>2023 AEU</rights><rights>Copyright © 2023 AEU. Published by Elsevier España, S.L.U. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c241t-3735aaac8df0a22723ea82be05386316c9e59172f9b119a2a4582235cf7b8ba83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37838326$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bostancı, C.</creatorcontrib><creatorcontrib>Demir, D.Ö.</creatorcontrib><title>The effect of the combination of prostate-specific antigen derivatives with multiparametric prostate magnetic resonance imaging scores on the negative predictive value of it in grey zone patients</title><title>Actas urológicas españolas (English ed.)</title><addtitle>Actas Urol Esp (Engl Ed)</addtitle><description><![CDATA[To calculate the negative predictive value (NPV) of negative multiparametric prostate magnetic resonance imaging (mpMRI), accepted as no lesions on images, when combined with prostate-specific antigen density (PSAD) and free/total prostate-specific antigen ratio (f/t PSA) in grey zone patients.
191 patients with PSA levels between 4−10 mg/mL and negative mpMRI were analyzed. The NPV of negative mpMRI was calculated according to a PSAD level of <0.15 ng/mL/mL, f/t PSA ratio of >0.15, and a combination of both. Patients were divided into three risk groups according to these two parameters, which were PSAD 0.01−0.07 ng/mL/mL and f/t PSA ratio ≥25 in a low-risk group, PSAD 0.08−0.15 ng/mL/mL, and f/t PSA ratio 0.15−0.24 in an intermediate-risk group and high-risk group, in which PSAD > 0.15 ng/mL/mL and f/t PSA ratio <15.
NPV of negative mpMRI was 92.6% for clinically significant prostate carcinoma (CSPCa). It increased to 97.5% in a low-risk group and decreased to 33.3% for CSPCa in a high-risk group. NPV of negative mpMRI results were so close when combined with PSAD < 0.15 ng/mL/mL and f/t PSA > 15.
f/t PSA ratio might also be used to increase the NPV of mpMRI, like PSAD. We advise not to avoid prostate biopsy when PSAD is >0.15 ng/mL/mL and the f/t PSA ratio is <0.15. However, we need randomized controlled studies with more patients to confirm our study.
Calcular el valor predictivo negativo (VPN) de la resonancia magnética multiparamétrica (RMmp) de próstata negativa, definida como la ausencia de lesiones en las imágenes, cuando se combina con la densidad del PSA (DPSA) y el índice PSA libre/total (PSA l/t) en pacientes cuyo PSA se encuentra en la zona gris (4−10 mg/mL).
Se analizaron 191 pacientes con niveles de PSA entre 4 y 10 mg/mL y RMmp negativa. El VPN de la RMmp negativa se calculó de acuerdo con un nivel de DPSA < 0,15 ng/mL/mL, un índice PSA l/t > 0,15 y una combinación de ambos. Los pacientes se dividieron en tres grupos de riesgo según estos dos parámetros, de la siguiente manera: DPSA 0,01−0,07 ng/mL/mL e índice PSA l/t ≥ 25 en el grupo de bajo riesgo; DPSA 0,08−0,15 ng/mL/mL e índice PSA l/t 0,15−0,24 en el grupo de riesgo intermedio; DPSA > 0,15 ng/mL/mL e índice PSA l/t PSA < 15 en el grupo de riesgo alto.
El VPN de la RMmp negativa fue del 92,6% para el carcinoma de próstata clínicamente significativo (CPCS). El VPN aumentó a 97,5% en el grupo de riesgo bajo, y disminuyó a 33,3% en el de riesgo alto. El resultado al combinar la RMmp negativa con la DPSA < 0,15 ng/mL/mL fue muy similar al de su combinación con el PSA l/t > 15.
el índice PSA l/t también podría utilizarse para aumentar el VPN de la RMmp, al igual que la DPSA. No recomendamos evitar la biopsia de próstata con una DPSA > 0,15 ng/mL/mL y un índice PSA l/t < 0,15. Sin embargo, se requieren estudios controlados aleatorizados con más pacientes para confirmar los hallazgos de nuestro estudio.]]></description><subject>Densidad del antígeno prostático específico</subject><subject>Free/total prostate-specific antigen ratio</subject><subject>Humans</subject><subject>Male</subject><subject>Multiparametric Magnetic Resonance Imaging</subject><subject>Multiparametric prostate magnetic resonance imagin</subject><subject>Predictive Value of Tests</subject><subject>Prostate - diagnostic imaging</subject><subject>Prostate - pathology</subject><subject>Prostate specific antigen density</subject><subject>Prostate-Specific Antigen</subject><subject>Prostatic Neoplasms - diagnostic imaging</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Resonancia magnética multiparamétrica de próstata</subject><subject>Índice de antígeno prostático específico libre/total</subject><issn>2173-5786</issn><issn>2173-5786</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9Uctu1TAQtRCIVqV_gJCXbHIb23k4GyRU8ahUiU1ZWxNnkvoqsS-2c1H5PX6MSW-LWOGNx0dn5njOYeytKHeiFM3Vfgd2jQF3spSKoF1ZVi_YuRStKupWNy__qc_YZUr7kk5TqbpTr9mZarXSSjbn7PfdPXIcR7SZh5Fnetmw9M5DdsFv0CGGlCFjkQ5o3egsB5_dhJ4PGN2ReEdM_KfL93xZ5-wOEGHBHIn43MoXmDxmQiKm4MFb5I4w5yeebCCQk9am7XF6HEitODj7WB5hXnH7icvceT5FfOC_gicOUdHn9Ia9GmFOePl0X7Dvnz_dXX8tbr99ubn-eFtYWYlcqFbVAGD1MJYgZSsVgpY9lrXSjRKN7bDuRCvHrheiAwlVraVUtR3bXveg1QV7f5pLe_1YMWWzuGRxnsFjWJORum2VJpc7olYnqiULUsTRHCJtHB-MKM2WoNmbU4JmS3BDKUFqe_eksPYLDn-bnvMiwocTAWnPo8NokiUPLJkVKUIzBPd_hT8egrO9</recordid><startdate>202404</startdate><enddate>202404</enddate><creator>Bostancı, C.</creator><creator>Demir, D.Ö.</creator><general>Elsevier España, S.L.U</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202404</creationdate><title>The effect of the combination of prostate-specific antigen derivatives with multiparametric prostate magnetic resonance imaging scores on the negative predictive value of it in grey zone patients</title><author>Bostancı, C. ; Demir, D.Ö.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c241t-3735aaac8df0a22723ea82be05386316c9e59172f9b119a2a4582235cf7b8ba83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Densidad del antígeno prostático específico</topic><topic>Free/total prostate-specific antigen ratio</topic><topic>Humans</topic><topic>Male</topic><topic>Multiparametric Magnetic Resonance Imaging</topic><topic>Multiparametric prostate magnetic resonance imagin</topic><topic>Predictive Value of Tests</topic><topic>Prostate - diagnostic imaging</topic><topic>Prostate - pathology</topic><topic>Prostate specific antigen density</topic><topic>Prostate-Specific Antigen</topic><topic>Prostatic Neoplasms - diagnostic imaging</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Resonancia magnética multiparamétrica de próstata</topic><topic>Índice de antígeno prostático específico libre/total</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bostancı, C.</creatorcontrib><creatorcontrib>Demir, D.Ö.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Actas urológicas españolas (English ed.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bostancı, C.</au><au>Demir, D.Ö.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effect of the combination of prostate-specific antigen derivatives with multiparametric prostate magnetic resonance imaging scores on the negative predictive value of it in grey zone patients</atitle><jtitle>Actas urológicas españolas (English ed.)</jtitle><addtitle>Actas Urol Esp (Engl Ed)</addtitle><date>2024-04</date><risdate>2024</risdate><volume>48</volume><issue>3</issue><spage>238</spage><epage>245</epage><pages>238-245</pages><issn>2173-5786</issn><eissn>2173-5786</eissn><abstract><![CDATA[To calculate the negative predictive value (NPV) of negative multiparametric prostate magnetic resonance imaging (mpMRI), accepted as no lesions on images, when combined with prostate-specific antigen density (PSAD) and free/total prostate-specific antigen ratio (f/t PSA) in grey zone patients.
191 patients with PSA levels between 4−10 mg/mL and negative mpMRI were analyzed. The NPV of negative mpMRI was calculated according to a PSAD level of <0.15 ng/mL/mL, f/t PSA ratio of >0.15, and a combination of both. Patients were divided into three risk groups according to these two parameters, which were PSAD 0.01−0.07 ng/mL/mL and f/t PSA ratio ≥25 in a low-risk group, PSAD 0.08−0.15 ng/mL/mL, and f/t PSA ratio 0.15−0.24 in an intermediate-risk group and high-risk group, in which PSAD > 0.15 ng/mL/mL and f/t PSA ratio <15.
NPV of negative mpMRI was 92.6% for clinically significant prostate carcinoma (CSPCa). It increased to 97.5% in a low-risk group and decreased to 33.3% for CSPCa in a high-risk group. NPV of negative mpMRI results were so close when combined with PSAD < 0.15 ng/mL/mL and f/t PSA > 15.
f/t PSA ratio might also be used to increase the NPV of mpMRI, like PSAD. We advise not to avoid prostate biopsy when PSAD is >0.15 ng/mL/mL and the f/t PSA ratio is <0.15. However, we need randomized controlled studies with more patients to confirm our study.
Calcular el valor predictivo negativo (VPN) de la resonancia magnética multiparamétrica (RMmp) de próstata negativa, definida como la ausencia de lesiones en las imágenes, cuando se combina con la densidad del PSA (DPSA) y el índice PSA libre/total (PSA l/t) en pacientes cuyo PSA se encuentra en la zona gris (4−10 mg/mL).
Se analizaron 191 pacientes con niveles de PSA entre 4 y 10 mg/mL y RMmp negativa. El VPN de la RMmp negativa se calculó de acuerdo con un nivel de DPSA < 0,15 ng/mL/mL, un índice PSA l/t > 0,15 y una combinación de ambos. Los pacientes se dividieron en tres grupos de riesgo según estos dos parámetros, de la siguiente manera: DPSA 0,01−0,07 ng/mL/mL e índice PSA l/t ≥ 25 en el grupo de bajo riesgo; DPSA 0,08−0,15 ng/mL/mL e índice PSA l/t 0,15−0,24 en el grupo de riesgo intermedio; DPSA > 0,15 ng/mL/mL e índice PSA l/t PSA < 15 en el grupo de riesgo alto.
El VPN de la RMmp negativa fue del 92,6% para el carcinoma de próstata clínicamente significativo (CPCS). El VPN aumentó a 97,5% en el grupo de riesgo bajo, y disminuyó a 33,3% en el de riesgo alto. El resultado al combinar la RMmp negativa con la DPSA < 0,15 ng/mL/mL fue muy similar al de su combinación con el PSA l/t > 15.
el índice PSA l/t también podría utilizarse para aumentar el VPN de la RMmp, al igual que la DPSA. No recomendamos evitar la biopsia de próstata con una DPSA > 0,15 ng/mL/mL y un índice PSA l/t < 0,15. Sin embargo, se requieren estudios controlados aleatorizados con más pacientes para confirmar los hallazgos de nuestro estudio.]]></abstract><cop>Spain</cop><pub>Elsevier España, S.L.U</pub><pmid>37838326</pmid><doi>10.1016/j.acuroe.2023.10.004</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2173-5786 |
| ispartof | Actas urológicas españolas (English ed.), 2024-04, Vol.48 (3), p.238-245 |
| issn | 2173-5786 2173-5786 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2877380649 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Densidad del antígeno prostático específico Free/total prostate-specific antigen ratio Humans Male Multiparametric Magnetic Resonance Imaging Multiparametric prostate magnetic resonance imagin Predictive Value of Tests Prostate - diagnostic imaging Prostate - pathology Prostate specific antigen density Prostate-Specific Antigen Prostatic Neoplasms - diagnostic imaging Prostatic Neoplasms - pathology Resonancia magnética multiparamétrica de próstata Índice de antígeno prostático específico libre/total |
| title | The effect of the combination of prostate-specific antigen derivatives with multiparametric prostate magnetic resonance imaging scores on the negative predictive value of it in grey zone patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T13%3A43%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effect%20of%20the%20combination%20of%20prostate-specific%20antigen%20derivatives%20with%20multiparametric%20prostate%20magnetic%20resonance%20imaging%20scores%20on%20the%20negative%20predictive%20value%20of%20it%20in%20grey%20zone%20patients&rft.jtitle=Actas%20urol%C3%B3gicas%20espa%C3%B1olas%20(English%20ed.)&rft.au=Bostanc%C4%B1,%20C.&rft.date=2024-04&rft.volume=48&rft.issue=3&rft.spage=238&rft.epage=245&rft.pages=238-245&rft.issn=2173-5786&rft.eissn=2173-5786&rft_id=info:doi/10.1016/j.acuroe.2023.10.004&rft_dat=%3Cproquest_cross%3E2877380649%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2877380649&rft_id=info:pmid/37838326&rft_els_id=S2173578623001154&rfr_iscdi=true |